In addition, overexpression of GGT-II enzyme substrates such as Rab25, Rab5 and Rab7, has been reported in breast, ovarian, prostate and bladder cancers, and for some of these substrate mutation is a determinant of the aggressiveness of the cancer and a predictor of poor outcome59. Here, RAB25 is linked to urinary bladder cancer.